The Global Fund and pharmacovigilance systems in resourcelimited settings

The Lancet

Volumn 381, Issue 9875, 2013, Pages 1360-

  Xueref, S ^a   Daviaud, J ^b   Pal, S ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COLOMBIA; DEVELOPING COUNTRY; DRUG SURVEILLANCE PROGRAM; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE DELIVERY; INDONESIA; INFORMATION; LETTER; LIBERIA; MALARIA; MOROCCO; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK; SOUTH AFRICA; THAILAND; TUBERCULOSIS; VIET NAM; HUMAN; RESOURCE MANAGEMENT; WORLD HEALTH ORGANIZATION;

DRUG;

EID: 84876231521     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60885-5     Document Type: Letter

References (4)

1. Raine JM. Drug safety: reporting systems for the general public. BMJ 2012; 345: e4916.
2. Bakare N, Edwards IR, Stergachis A, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med 2011; 8: e1001054.
3. Global Fund to fight AIDS, Tuberculosis and Malaria. Final report of the third board meeting. http://www.theglobalfund.org/en/board/meetings/fourth/ documents/(accessed March 27, 2013).
4. Global Fund to fight AIDS, Tuberculosis and Malaria. Report of the High Level Independent Review Panel on Fiduciary Controls and Oversight Mechanisms. http://www.theglobalfund.org/en/highlevelpanel/report/(accessed March 27, 2013).